MicroRNA 662 (miR-662)

MicroRNA 662 (miR-662, also called hsa-miR-662 or MIR662) is a small, non-coding RNA of the microRNA family, expressed as a precursor transcript and processed to a mature ~22-nucleotide RNA that regulates gene expression at the post-transcriptional level[1]. miR-662 functions by binding imperfectly to complementary sequences in the 3′ untranslated regions (UTRs) of target mRNAs, leading to translational inhibition or mRNA destabilization, often through incorporation into the RNA-induced silencing complex (RISC)[1][8]. In breast cancer, high serum levels of miR-662 are associated with increased risk of bone metastasis and may be used as an independent prognostic marker at diagnosis[2][3][7]. miR-662 is involved in modulating cancer cell proliferation, migration, stemness, and the inhibition of osteoclast differentiation at early metastatic stages, contributing to cancer progression[2][3][7]. It has also been implicated in the regulation of CREB1, a transcription factor, potentially influencing cardiac or neurological diseases[5]. As a regulatory RNA, it is not a receptor, enzyme, or transporter, nor is it currently a direct therapeutic target for small molecules or biologics, though research is ongoing to understand its potential for therapeutic manipulation[6].

Other names

hsa-miR-662MIR662MIRN662